Hormone therapy and sleep

Menopausal hormone therapy improves sleep for one main reason: it is the most effective treatment for the hot flashes and night sweats that wake women up. When vasomotor symptoms are the problem, randomized trials show better sleep quality on hormone therapy; when they are not, the trials show no benefit. That makes the first question not whether to take hormones for sleep, but what is actually waking you.

What hormone therapy is

Menopausal hormone therapy (also called HT or MHT) replaces some of the estrogen the ovaries stop making. According to ACOG, there are two basic forms. Estrogen alone is used by women who have had a hysterectomy. Women who still have a uterus take estrogen plus a progestogen, because estrogen on its own thickens the uterine lining and raises the risk of endometrial cancer; the progestogen protects against that.

Systemic estrogen comes as pills, skin patches, gels and sprays, and travels through the bloodstream to the whole body. Low-dose vaginal estrogen (rings, tablets, creams) acts locally on vaginal and urinary tissue and is used for dryness and urinary symptoms, not for hot flashes or sleep. If you are unsure whether you have reached the stage where this applies, start with what is perimenopause.

Why it can help sleep in perimenopause

In the Study of Women’s Health Across the Nation, more frequent hot flashes raised the odds of trouble falling asleep, staying asleep and waking early, and falling estradiol was independently linked to the first two. Postmenopausal women using hormones generally had lower odds of disturbed sleep than those who were not. Both observations point to the same mechanism: night sweats are a direct cause of awakenings, and estrogen stops them.

Whether estrogen also improves sleep through pathways unrelated to hot flashes is less clear. Estrogen affects temperature regulation and several brain systems involved in sleep, which makes a direct effect plausible, but the trials that separate women with and without hot flashes do not find a benefit in the group without them. For the moment, the practical conclusion is that hormone therapy treats sleep problems caused by vasomotor symptoms. See why perimenopause wakes you at 3 a.m. for how a night sweat turns into an hour awake.

What hormone therapy will not fix

Sleep problems that are not driven by hot flashes need a different approach:

• Insomnia disorder, where months of broken nights have trained the body to wake, responds to cognitive behavioral therapy for insomnia. See CBT-I for menopause insomnia.
• Sleep apnea, whose risk rises after menopause and which often presents as insomnia in women. See sleep apnea in women after 40. Observational data link hormone use to lower apnea prevalence, but hormone therapy is not a treatment for apnea.
• Depression and anxiety disorders, which need their own evaluation and treatment; see perimenopausal depression.
• Restless legs, pain, reflux, nocturia, alcohol and medications.

A sleep diary that records night sweats alongside awakenings will show quickly whether the two line up.

What the evidence shows, ranked

Strong: relief of hot flashes and night sweats. The Menopause Society’s 2022 position statement describes hormone therapy as the most effective treatment for vasomotor symptoms, and ACOG calls systemic estrogen the best treatment for hot flashes and night sweats. This is the foundation of its effect on sleep.

Moderate: better sleep quality in women with hot flashes. A systematic review in Endocrine identified 42 randomized trials of hormone therapy with sleep outcomes and pooled seven of them (15,468 women). In women who had vasomotor symptoms at baseline, hormone therapy improved sleep quality with a standardized mean difference of -0.54, which the authors rated moderate-quality evidence. When women without hot flashes were analyzed separately or combined, there was no difference.

Moderate, modest in size: the MsFLASH trial. This double-blind trial randomized 339 perimenopausal and postmenopausal women with at least two bothersome hot flashes a day to low-dose oral estradiol (0.5 mg/day), low-dose venlafaxine (75 mg/day) or placebo for 8 weeks. Insomnia Severity Index scores fell 4.1 points with estradiol, 5.0 with venlafaxine and 3.0 with placebo; Pittsburgh Sleep Quality Index scores improved 2.2, 2.3 and 1.2 points respectively. The authors described both active treatments as modestly reducing insomnia symptoms and improving sleep quality. Two points follow: the trial used a low dose, so it may not reflect standard regimens, and a nonhormone option performed comparably.

Alternatives for women who cannot use hormones. ACOG lists antidepressants, gabapentin and clonidine among nonhormone medications used to reduce hot flashes and ease sleep problems (The Menopause Society now advises against clonidine because of its side effects; see our non-hormonal treatments guide), and notes that few plant and herbal supplements have been studied for safety or effectiveness. The Menopause Society’s 2023 nonhormone statement adds cognitive behavioral therapy and fezolinetant as evidence-based options.

Risks, and the 2025 label change

The Menopause Society’s position is that risks differ by type, dose, duration, route, timing of initiation and whether a progestogen is used, and that treatment should be individualized and re-evaluated periodically. For women younger than 60 or within 10 years of menopause onset who have no contraindications, it rates the benefit-risk ratio as favorable for treating bothersome hot flashes and preventing bone loss. For women who start more than 10 years after menopause or after age 60, the balance is less favorable because absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia are higher.

ACOG’s patient guidance adds specifics. Combined estrogen-progestin therapy is associated with a small increased risk of breast cancer. Both combined and estrogen-only therapy carry a small risk of stroke and blood clots, which rises with age and other conditions; patches, sprays and rings may pose less clot risk than pills. Systemic hormone therapy is usually not recommended for women who have had breast or endometrial cancer, stroke, heart attack, blood clots or liver disease. Common side effects include spotting (which usually stops within six months), breast tenderness, bloating and headaches. ACOG also cautions that compounded bioidentical hormones are not FDA-regulated and vary in strength and purity.

On November 10, 2025, the FDA announced it was removing the boxed warnings about cardiovascular disease, breast cancer and probable dementia from hormone therapy products for menopause, citing a scientific review of evidence gathered since the warnings were added in the early 2000s. The boxed warning about endometrial cancer for systemic estrogen-alone products remains. The practical meaning is that labels will better reflect the age- and timing-dependent picture described above, not that the risks have disappeared.

When to see a clinician

Talk to an ob-gyn or a clinician found through how to find a menopause specialist if night sweats are waking you regularly and you want to weigh hormone therapy against the alternatives. Bring your sleep diary and symptom check results; they shorten the conversation.

Seek care promptly, whether or not you use hormone therapy, if you have:

• Vaginal bleeding after menopause, or bleeding on hormone therapy that is heavy or persists beyond the first months
• Chest pain, sudden shortness of breath, or a swollen, painful calf
• Sudden weakness, numbness, severe headache or trouble speaking
• Snoring with gasping or daytime sleepiness, which suggests sleep apnea rather than hot flashes
• Low mood or anxiety that is hard to control, or thoughts of harming yourself (call or text 988, the Suicide & Crisis Lifeline)

If you start hormone therapy, ACOG recommends revisiting the decision with your clinician every year, based on your symptoms, risks and benefits at that point.